Evolution of clinical trials was a major theme among executives who at the end of 2021 shared their predictions for 2022. Remote, or decentralized, trials was a common talking point, as was the harnessing of technological advances in capturing and analyzing data.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
Decentralization, Diversity And Data Analytics Are Drivers Of Change
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
More from Scrip Asks
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.